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GENE THERAPY AS A VIABLE THERAPEUTIC APPROACH FOR 
PARKINSON’S DISEASE 
 
CHANTAL CHAMMAS 
ABSTRACT 
 Parkinson’s Disease (PD) is a neurological disorder affecting the basal ganglia in 
which the loss of dopaminergic neurons in the substantia nigra pars compacta (SNpc) 
manifests as a complex array of motor and non-motor symptoms. Due to the lack of 
treatment for preventing the neurodegenerative process of PD, the only available therapy 
options involve managing the clinical symptoms resulting from dopamine (DA) depletion 
in the basal ganglia. The most widely implemented treatment is the pharmacological 
agent L-DOPA which serves as the precursor to dopamine. Although L-DOPA 
administration is initially effective in improving motor function and patient life quality, 
its therapeutic effect diminishes as PD pathology progressively worsens over time and 
side effects such as L-DOPA induced dyskinesia become apparent. Researchers are now 
seeking to alleviate the symptoms of PD on a molecular basis with gene therapy in which 
the three therapeutic strategies target specific genes involved in either increasing 
dopamine production, regulating the pathways of the basal ganglia, or protecting 
dopaminergic neurons of the nigrostriatal pathway. Current research is focused on 
investigating the efficacy and overall safety of gene therapy through delivery of the genes 
responsible for aromatic L-acid decarboxylase (AADC), glutamic acid decarboxylase 
(GAD), glial cell derived neurotrophic factor (GDNF), and neurturin (NRTN). Although 
		 vi 
these methods of gene therapy are relatively new and still developing, they present a 
promising direction for PD treatment. In this review, the various gene therapy strategies 
designed for improving parkinsonism are evaluated for safety and efficacy.    
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INTRODUCTION 
 
  Parkinson’s Disease (PD) is a prominent neurodegenerative disease characterized 
by the degradation of dopaminergic neurons in the substantia nigra pars compacta (SNpc) 
resulting in the loss of dopamine in the basal ganglia (Kalia & Lang, 2015).  This 
depletion of dopamine levels disrupts the normal function of the basal ganglia and 
consequently impairs the motor pathways essential for initiating and fine tuning 
movement. PD is therefore considered a movement disorder in which patients classically 
exhibit a lack of movement control in addition to presenting certain non-motor symptoms 
that affect cognition (Tysnes & Storstein, 2017). Second to Alzheimer’s disease, PD is 
deemed the most prevalent neurodegenerative disorder in the world (Dorsey et al., 2007) 
in which approximately 1% of the population is diagnosed at age 60 or above (Tysnes & 
Storstein, 2017) with a 50% projected increase in PD diagnoses by the year 2030 (Dorsey 
et al., 2007). Due to the slow progressive nature of the disease, a proper PD diagnosis is 
made only after the neurophysiological pathology manifests as clinical symptoms which 
may occur up to 20 years after the disease first develops. This period regarded as the pre-
motor stage is characterized by a compilation of non-motor symptoms such as decreased 
olfaction, gastrointestinal issues, sleep disorders, and mood changes which may be 
difficult to recognize as symptoms predictive of PD since they are also considered normal 
effects of aging (Siderowf & Lang, 2012). The hallmark features of PD used to correctly 
diagnosis patients include resting tremor, rigidity, akinesia or bradykinesia, and postural 
instability (Hughes, Daniel, Kilford, & Lees, 1992).  
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Pathology 
The neuropathological evidence for PD is demonstrated through the loss of 
dopaminergic neurons in the SNpc in which neurons communicating with the putamen by 
means of the nigrostriatal pathway are most severely impaired (Dickson et al., 2009). As 
a result of this neurodegeneration, the motor circuity of the basal ganglia linking the 
cerebral cortex to specific thalamic nuclei undergoes significant organizational changes 
that lead to an inability to control voluntary movements (Blandini, Nappi, Tassorelli, & 
Martignon, 2000).   
The basal ganglia is a collection of five nuclei or groups of neurons (caudate 
nucleus, putamen, globus pallidus, substantia nigra, and subthalamic nucleus) embedded 
in the cerebral cortex. The nuclei interact with one another through two distinct 
pathways, the direct and indirect pathway, for exerting control over motor functions 
(Blandini et al., 2000). The basal ganglia is organized such that the main input nucleus, 
striatum, uses the direct and indirect pathways to relay information to basal ganglia ouput 
nuclei; globus pallidus, substantia nigra, and subthalamic nucleus. The striatum, 
consisting of both the caudate nucleus and putamen, receives excitatory neural input from 
the cortex and dopaminergic input from the substantia nigra pars compacta (SNpc). When 
the striatum is activated, it transmits inhibitory signals to the internal or medial globus 
pallidus (GPi). As the main output nucleus of the basal ganglia, GPi is responsible for 
relaying information to the thalamus so it may ultimately reach the motor cortex. When 
GPi neurons receive inhibitory signals from the striatum, the GPi activity of transmitting 
inhibitory signals to the thalamus decreases. As a result, the thalamus is disinhibited. This 
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circuitry is the direct pathway in which GABAergic neurons of the striatum communicate 
synaptically with the the substantia nigra pars reticulata (SNpr) and GPi (Blandini et al., 
2000). Through the indirect signaling pathway, the GABAergic neurons of the striatum 
transmit information to the lateral or external globus pallidus (GPe) which decreases GPe 
activity. When GPe neurons receive inhibitory signals from the striatum, the GPe activity 
of sending inhibitory signals to the subthalamic nucleus (STN) decreases. Consequently, 
the STN increases its activity leading to an increase of excitatory signals to GPi neurons 
and inhibition of the thalamus (Blandini et al., 2000).  
 
 
 
Fig 1. Functional organization of the direct and indirect pathways of the basal 
ganglia (Roshan, Tambo, & Pace, 2016). 
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The PD pathophysiology of degenerating dopaminergic neurons within the 
nigrostriatal pathway disrupts both the direct and indirect pathways. This loss of DA 
neurons within the SNpc interferes with the striatum’s ability to integrate cortical inputs 
and exert proper control on GPi neurons via the direct and indirect pathway. Inhibition 
within the direct pathway mechanism prevents further motor activation. In addition, the 
impairment of the nigrostriatal pathway affects the indirect pathway by increasing GPe 
inhibition and consequently reducing the inhibition of the STN which leads to an overall 
increase in thalamic inhibition and inability to perform motor functions (Blandini et al., 
2000).  
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Fig 2. Effect of PD pathology on the functional organization of the direct and 
indirect pathways of the basal ganglia. The loss of DA neurons in the SNpc leads to a 
series of changes in the basal ganglia circuity in which STN hyperactivity results in 
increased GPe and SNpr GABAergic output to the thalamus. The thickness of projecting 
arrows indicates the extent of pathway activation. SNc = substantia nigra pars compacta; 
STN = subthalamic nucleus; LGP = lateral (external) globus pallidus; MGP = medial 
(internal) globus pallidus; SNr = substantia nigra pars reticulata (Blandini et al., 2000).  
 
Current Treatment 
Although there is currently no disease modifying cure for Parkinson’s Disease, 
several effective treatment methods exist for reducing its clinical symptoms. The most 
routine treatment strategy involves pharmaceutical agents designed to either increase 
intracerebral DA levels or activate DA receptors in which L-DOPA, DA agonists, 
monoamine oxidase type B inhibitors, and amantadine are typically the drugs of choice. 
Therapy is often started when clinical symptoms begin to cause the patient difficulty in 
performing daily functions and activities and not given at the time of diagnosis (Kalia & 
Lang, 2015). For advanced cases of PD, L-DOPA, the precursor to dopamine, is 
prescribed as the drug of choice providing the most therapeutic benefit, but not void of 
the negative side effects of extreme nausea and vomiting. Long term use of L-DOPA 
however can induce adverse effects demonstrated as response fluctuations and 
dyskinesias (Olanow et al., 2004). After five years of successful L-DOPA therapy, 
approximately 50% of PD patients reported a decreased dose response to L-DOPA in 
which the initial therapeutic effect of each L-DOPA dose lasts for a shorter period of time 
referred to as the wearing off fluctuation (Verhagen, 2002). In addition, as PD pathology 
progresses and patients continue pharmacological treatment with L-DOPA, the 
therapeutic effect of L-DOPA further decreases and takes on an unpredictable nature in 
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which patients experience motor swings regarded as the on-off phenomenon. During the 
ON phase, patients feel the therapeutic benefit of L-DOPA treatment and maintain 
control of their motor symptoms, whereas patients in the OFF phase respond poorly to L-
DOPA treatment and display impaired motor function through the reemergence of motor 
symptoms (Lees, 1989). As patients fluctuate between the ON and OFF states, it becomes 
increasingly difficult to determine the correlation between the time at which L-DOPA 
medication was taken and reappearance of PD motor symptoms and involuntary 
movements (Verhagen, 2002). 
Deep brain stimulation (DBS), a recent surgical approach to treating the motor 
symptoms of PD, has demonstrated significant promise in improving the quality of life 
for PD patients in addition to decreasing the dose of L-DOPA required to elicit a 
therapeutic response (Fasano, Daniele, & Albanese, 2012). This invasive procedure 
targets the subthalamic nucleus and internal globus pallidus to elicit improved motor 
function. The DBS treatment option is introduced to patients nearly 10 years after PD 
diagnosis and implemented as a secondary therapy to L-DOPA (Kalia & Lang, 2015).   
Thus far, the main therapeutic approaches for managing PD symptoms are 
pharmacological and fail to address the molecular basis of PD. Through targeting PD on 
a genetic level, patients are given the opportunity to potentially improve their PD induced 
symptoms without experiencing additional adverse side effects associated with the 
current available treatments.  
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Gene Therapy 
Gene therapy is an alternative therapeutic method for targeting the symptoms of 
PD in which a specific gene of interest is delivered to the involved brain region in an 
effort to improve motor function. This process of gene therapy is based on providing 
targeted cells with the appropriate genetic information necessary to produce a particular 
protein for alleviating a condition. The advantage of gene therapy over other PD 
treatment strategies is its ability to limit off target side effects due to its extreme 
specificity (Stayte & Vissel, 2014). The gene of interest is safely transported into the 
neural tissues through the use of a viral vector in which retroviruses, adeno-associated 
viruses (AAV), or adenoviruses are most commonly used (Mochizuki, Miura, Shimada, 
& Mizuno, 2002). Treatment by means of gene therapy offers several different 
approaches to reduce the presence of PD symptoms caused by the destruction of 
dopaminergic neurons of the nigrostriatal pathway. The application of gene therapy for 
the delivery of genes coding for aromatic L-amino acid decarboxylase (AADC) as well as 
the triple gene approach of tyrosine hydroxylase, aromatic L-amino acid decarboxylase, 
and GTP-cyclohydrolase-1 (AADC-TH-GCH) work to improve parkinsonism through 
increasing levels of dopamine in the striatum (Christine et al., 2009; Azzouz et al., 2002). 
Another PD gene therapy strategy relies on the infusion of the gene responsible for 
glutamic acid-decarboxylase (GAD) in an effort to regulate the neural circuitry of the 
basal ganglia through increasing GABA production (Kaplitt et al., 2007). Gene therapy 
has also been implemented for the delivery of neurotrophic factors such as glial cell 
derived neurotrophic factor (GDNF) and neurturin (NRTN) which unlike the other 
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methods of gene therapy present the possibility of preventing further PD pathology 
progression by protecting the targeted dopaminergic neurons from further 
neurodegeneration (Gill et al., 2003; Marks et al., 2008) As a relatively novel treatment 
for PD, researchers are actively conducting ongoing studies to better understand the 
potential benefits as well as safety associated with each gene therapy strategy. Compared 
to the traditional PD treatments, gene therapy may offer patients the benefits of reduced 
L-DOPA doses accompanied by fewer motor fluctuations and extended periods of time in 
the ON phase (Christine et al., 2009; Azzouz et al., 2002; Kaplitt et al., 2007). Gene 
therapy could ultimately improve patient quality of life through enhancing the therapeutic 
effect of L-DOPA treatment while decreasing the L-DOPA associated negative side 
effects. 
 
Unified Parkinson’s Disease Rating Scale (UPDRS) 
The vast majority of research studies utilize the Unified Parkinson’s Disease 
Rating Scale (UPDRS) to clinically evaluate the benefits of newly developed treatment 
methods. The UPDRS scale is divided into four parts to individually examine behavioral 
flaws associated with PD (Fahn, Elton, & Members of the UPDRS Development 
Committee, 1987). UPDRS part I focuses on the presentation of non motor PD symptoms 
such as decreased intellectual function, depression, anxiety, and hallucinations. UPDRS 
part II targets the PD patient’s ability or inability to engage in activities of daily living 
including getting dressed, walking, eating, and performing regular daily tasks. Part III of 
the UPDRS scale is dedicated to assessing PD motor symptoms which are often 
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considered the hallmark features of PD. These symptoms include reduced facial 
expressions, rigidity, bradykinesia, balance difficulties, resting tremor, and shuffling gait. 
The final part of the UPDRS scale, Part IV, is responsible for analyzing the treatment 
induced motor complications such as dyskinesia, dystonia, and motor fluctuations 
(Bohannon, Nair, & Green, 2019). Part III of the UPDRS scale is further subdivided into 
patient ON and OFF states to obtain the most unbiased evaluation of each patient’s 
clinical impairment resulting from PD pathology (Mittermeyer et al., 2012). By including 
the distinction between patient behavior in the ON and OFF states, researchers are able to 
distinguish which reported symptoms are implicated to PD or simply drug induced. 
Within each section of the UPDRS questionnaire, patients are prompted to rank the 
degree of intensity and/or frequency to which they experience specific behavioral 
symptoms on a scale of 0 to 4. The scores respectively indicate the following clinical 
responses of normal, slight, mild, moderate, and severe from 0 to 4 in which higher 
scores correspond to increased disease severity and consequently greater disability 
(Mittermeyer et al., 2012). This systematic way of evaluating the clinical effects and 
manifestations of PD allows researchers to more accurately understand the level of 
behavioral impairment associated with each patient’s observed neuropathology. 
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PUBLISHED STUDIES  
 
 In an effort to combat the undesirable side effects associated with the current drug 
therapy strategy of regulating PD symptoms, researchers have begun investigating 
alternative treatment methods focusing on gene therapy. As a promising area of research 
for Parkinson’s disease, gene therapy offers three unique treatment approaches for 
alleviating the debilitating symptoms of PD: increasing dopamine production, modifying 
the pathways of the basal ganglia, and regenerating dopaminergic neurons. Each 
treatment method targets specific genes to initiate a mechanism for replenishing 
dopamine levels in the substantia nigra pars compacta (SNpc) in an effort to mitigate the 
symptoms of PD. Recent studies conducted to assess the therapeutic potential of gene 
therapy in PD involved genes coding for AADC, GAD, as well as the growth factors 
GDNF and NRTN. 
 
AADC Gene Therapy  
AADC is an endogenous enzyme responsible for metabolizing L-DOPA into DA 
within dopaminergic neurons of both the central and peripheral nervous system 
(Jamebozorgi et al., 2018). Although L-DOPA remains the primary treatment for 
reducing PD symptoms due to its ability to cross the blood brain barrier and restore DA 
levels (Nagatsu & Sawada, 2007), its therapeutic effect gradually decreases due to further 
degeneration of dopaminergic neurons in the SNpc, which ultimately leads to the loss of 
AADC (Jamebozorgi et al., 2018). Without substantial AADC levels, L-DOPA cannot be 
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converted into DA and results in a less effective therapy (Bankiewicz et al., 2006). By 
enhancing the expression of AADC through gene therapy, a sufficient supply of the 
enzyme would be available to carry out the conversion of L-DOPA to DA in surviving 
dopaminergic neurons (Nagatsu & Sawada, 2007).  
 
 
Fig 3. Biosynthesis of DA from L-DOPA. L-DOPA is decarboxylated by AADC 
to produce DA in the central nervous system. 
 
Studies performed on MPTP-lesioned nonhuman primates (NHP) showed that 
AADC gene therapy can increase striatal DA levels induced by L-DOPA drug treatment. 
In the research conducted by Bankiewicz et al, NHP PD models were injected with either 
therapeutic AAV-hAADC or nontherapeutic gene control AAV-LacZ in the striatum. The 
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Study evaluated the impact of the injections on AADC gene expression as well as 
improved motor behavior. Based on PET imaging using 6- [18F]-fluoro-meta-tyrosine 
([18F]FMT), the striatum of MPTP-lesioned monkeys treated with AAV-hAADC and 
with AAV-LacZ both initially had low AADC activity. However, several months after 
the viral infusion, the AAV-hAADC treatment group displayed increased AADC 
expression reaching its normal endogenous levels and maintained the same level of 
expression over a 2 year period (Bankiewicz et al., 2006). The behavioral response of the 
two treatment groups was then assessed with a clinical rating scale (CRS) in which the 
animals were scored based on the presentation of Parkinson-like behavior when no L-
DOPA was administered, 45 minutes after given the clinical recovery dose of L-DOPA, 
and 90 minutes after given the same L-DOPA dose. The AAV-hAADC treatment group 
exhibited improvement of the adverse motor side effects typically associated with L-
DOPA therapy at the clinical recovery dose (15 mg/kg) (Bankiewicz et al., 2006). The 
behavioral response of the two treatment groups was also assessed at a lower L-DOPA 
dose (3 mg/kg) which did not induce clinical recovery in control animals before vector 
infusions. The parkinsonian monkeys treated with AAV-hAADC demonstrated 
improvement of motor side effects at 6 months after infusion and continued to show 
increased clinical improvement until 12 months after AAV-hAADC treatment 
(Bankiewicz et al., 2006). The improved behavioral responses observed in the AAV-
hAADC treatment group suggest the infusion of AAV-hAADC in the striatum is 
responsible for increasing striatal DA levels and for restoring motor function.  
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AADC gene therapy research has progressed to phase I clinical trials under the 
guidance of Christine et al in which 10 patients diagnosed with moderately advanced PD 
were bilaterally infused with the AADC human gene vector AAV-hAADC in the 
putamen. Patients were divided into low and high gene vector dose groups. This study 
aimed to evaluate the level of safety involved in receiving intraputaminal infusions of 
AAV2-hAADC in human subjects diagnosed with PD as well as the potential benefit on 
motor fluctuations. Researchers found that the injection of AAV2-hAADC was well 
tolerated in PD patients. In addition, the gene therapy itself did not elicit adverse effects, 
but some adverse effects resulted from the surgery. This included one incidence of 
symptomatic and two incidences of asymptomatic intracranial hemorrhages after 
intraputaminal AAV22-hAADC injections. Clinical assessment of the subjects using the 
UPDRS showed significant improvement in each individual patient’s total and motor 
UPDRS scores during both the ON and OFF states. (Christine et al., 2009). 
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Fig 4. Effect of AAV2-hAADC treatment on UPDRS scores. Patient UPDRS 
scores in ON (right) and OFF (left) states recorded at baseline and 6 months after 
treatment. Total UPDRS scores (top) and motor UPDRS III scores (bottom) are 
shown (Christine et al., 2009). 
 
All 10 participating patients had been undergoing long term L-DOPA treatment 
that was continued after AAV2-hAADC infusions. The dose of L-DOPA medication was 
reduced for all subjects participating in the high vector dose group and three of the five 
subjects in the low vector dose group (Christine et al., 2009). This change in L-DOPA 
dosage was a result of patients experiencing more time in the ON state and reduced time 
in the OFF state. 
 
Table 1. Change in patient L-DOPA dose. Individual patient L-DOPA levels are 
recorded at baseline and 6 months after AAV2-hAADC vector infusion for the low and 
high vector dose groups. The mean decrease in L-DOPA dosage for the low and high 
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vector dose groups were stastically unsignificant, (p<0.06) and (p<0.16) respectively 
(Christine et al., 2009). 
 
 
Although the change in dose of L-DOPA was not significant (Table 1), the 
observed decrease in L-DOPA medication administered to patients supported the 
successful expression of AADC (Christine et al., 2009). As AADC expression increases 
with the injection of AAV2-hAADC vector, L-DOPA is able to produce more DA. The 
increase in DA production due to increased AADC would therefore result in decreased 
dependency on L-DOPA medication. 
 
The same group (Christine et al., 2009) performed a long term follow up study on 
the 10 subjects involved in the phase I clinical trial for AAV2-hAADC gene therapy in a 
continued effort to examine the safety and tolerability of the viral vector as well as the 
level of AADC expression years after the intraputaminal infusion. Of the original ten 
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subjects, one failed to return for follow ups after one year, and four received DBS 
treatment after beginning gene therapy, thereby leading to the exclusion of their data 
from the study (Mittermeyer et al., 2012). The remaining patients underwent annual 
[18F]FMT PET analysis for up to 5 years to evaluate AADC activity. Researchers noted 
that AADC gene expression was increased from baseline levels following AAV2-
hAADC infusion and that the increase persisted for a minimum of 4 years. This data 
supports the notion that striatal neurons maintained increased AADC gene expression 
several years after the vector infusion (Mittermeyer et al., 2012). However, the [18F]FMT 
uptake at 3 to 4 years after gene therapy displayed a slight downward trend relative to the 
increased uptake within the first 3 years following AAV2-hAADC treatment. This small 
decline in AADC activity seen at 3 to 4 years is believed to correspond to the progressive 
neurodegeneration characteristic of PD. The measured decrease in AADC expression is 
due to the loss of endogenous AADC produced by dopaminergic neurons of the SNpc as 
the DA neurons degenerate, not as a result of weakened AADC expression from AAV2-
hAADC therapy (Mittermeyer et al., 2012). The follow up study also reviewed the patient 
UPDRS ON and OFF state scores which demonstrated great improvement within the first 
year of treatment followed by consistent UPDRS measurements for the ON state but 
worse scores for the OFF state. Researchers attribute most of the initial change in 
UPDRS scores to the placebo effect and claim the patients’ maintained response to L-
DOPA displayed through the ON state UPDRS scores in spite of increased disease 
progression demonstrated by the poor OFF state UPDRS scores emphasizes the potency 
of AAV2-hAADC gene therapy (Mittermeyer et al., 2012). 
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A retrospective analysis of the AAV2-hAADC phase I clinical trial was also 
conducted to address concerns regarding the accuracy of the vector distribution and 
stereotactic surgical procedure (Valles et al., 2010). This study investigated T2 weighted 
magnetic resonance imaging (MRI) data acquired after the bilateral convection-enhanced 
delivery (CED) infusions of AAV2-AADC vector in the putamen in which AADC gene 
distribution was determined by the extent of T2 signaling (Valles et al., 2010). Based on 
preoperative MRI data, cannula tracts were correctly positioned to reach the putamen in 
each of the 9 participating patients. For 6 of the patients, T2 hyperintensity was observed 
at the cannula tracts, point of vector infusion, and directly surrounding the putamen. The 
T2 hyperintensity demonstrated in these regions of interest allowed researchers to 
conclude the CED AAV2-hAADC infusions successfully localized in the putamen 
(Valles et al., 2010). In addition, post operative [18F]FMT PET scans highlighting 
putaminal AADC activity were coregistered with the T2 MRI scans to display an overlap 
in FMT uptake and T2 hyperintensity, suggesting hAADC transgene expression is closely 
correlated to T2 hyperintensity. Thus, T2 weighted MRI data can be used to determine 
the volume of vector distribution (Vd) for AAv2-hAADC gene therapy (Valles et al., 
2010). 
 
Additional efforts to promote the development of AAV2-hAADC gene therapy 
were conducted by monitoring the effects of varying L-DOPA and carbidopa doses in 
fine tuning AADC transgene activity in unilaterally 6-hydroxydopamine (6-OHDA) 
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lesioned rats. Researchers were motivated by the fact that L-DOPA serves as the main 
driving force for producing substantial DA in the nigrostriatal pathway and that the 
activity of AADC is dependent on the presence of L-DOPA (Ciesielska, Sharma, Beyer, 
Forsayeth, & Bankiewicz, 2015). Through this study, PD rat models were infused with 
either the AADC transgene vector AAV2-hAADC or the control vector AAV2-GFP and 
each treated with L-DOPA/carbidopa 4:1 followed by treatment with L-DOPA alone. The 
AAV2-hAADC treated group exhibited increased rotational behavior indicating an 
increase in DA levels after the co-administration of L-DOPA/carbidopa, while the 
AAV2-GFP group failed to display these behavioral effects after receiving the same 
treatment. In addition, when treated with only L-DOPA, the AAV2-hAADC group 
demonstrated a significant loss of contralateral turning and striatal DA concentration 
(Ciesielska et al., 2015). 
 
 
Fig 5. Carbidopa regulates the L-DOPA induced behavioral response in AAV2-
hAADC rats. (A) Total number of contralateral turns in 2 hr of observation for the 
AAV2-GFP (black) and AAV2-AADC (white) treated rats reported on day 1, 5, 7, 8, and 
9. AAV2-GFP and AAV2-AADC rats received L-DOPA/carbidopa administration on 
days 1, 5, and 7 with carbidopa withdrawal starting on day 8. (B) Number of contralateral 
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turns recorded every 5 min over a 2 hr period for AAV2-hAADC rats on day 7, 8, and 9 
(Ciesielska et al., 2015). 
 
Thus, implementing carbidopa into the treatment regimen of L-DOPA with 
AAV2-hAADC gene therapy is most effective for restoring striatal DA concentrations to 
its functional level. 
 
A more recent study on AAV2-hAADC gene therapy focused on widening the 
target area for vector delivery to include not only the post-commissural putamen, but the 
entire putamen and caudate nucleus (Ciesielska et al., 2017) Through analyzing post-
mortem striatal tissue samples from PD subjects, AADC activity in addition to levels of 
DA and its metabolites DOPAC and HVA significantly decreased in comparison to their 
control counterparts seen in the anterior caudate and regions of the putamen (Ciesielska 
et al., 2017).  
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Fig 6. Decreased AADC activity correlates to decreased DA and DA metabolites in 
the anterior caudate and regions of the putamen. AADC activity, DA, DOPAC, and 
HVA levels measured in the five distinct striatal regions (top) of PD patients and control 
(Ciesielska et al., 2017). 
 
This data therefore suggests that future clinical studies should not limit AAV2-
hAADC vector infusion to only the post-commissural putamen since AADC depletion is 
observed throughout the putamen and caudate nucleus. 
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AADC-TH-GCH Gene Therapy 
As an extension of AADC gene therapy, the AADC-TH-GCH gene strategy 
involves three enzymes essential to DA production: AADC, tyrosine hydroxylase (TH), 
and GTP-cyclohydrolase-1 (GCH) (Nagatsu & Sawada, 2007). The biosynthetic pathway 
of DA begins with the conversion of tyrosine to L-DOPA by means of the enzyme TH in 
the presence of cofactor tetrahydrobiopterin (BH4). Although the hydroxylation of 
tyrosine to L-DOPA by TH is the rate limiting step in DA synthesis, TH cannot function 
properly without sufficient levels of BH4, which is a product of the enzyme GCH acting 
on guanosine triphosphate (GTP). Following the conversion of tyrosine to L-DOPA, L-
DOPA is then decarboxylated by the enzyme AADC to produce DA (Meiser, Windel, & 
Hiller, 2013).  
 
 
Fig 7. Schematic diagram of DA biosynthesis and metabolism (Bäck, 2014). 
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Through the AADC-TH-GCH gene therapy approach, the expression of these 
three crucial enzymes is upregulated in the non-deteriorating dopaminergic neurons of 
the striatum and generates an endogenous source of DA to replenish the deficit caused by 
the degeneration of nigrostriatal dopaminergic neurons. Thus, the standard treatment of 
L-DOPA oral administration as a means of supplying DA is no longer necessary when 
undergoing AADC-TH-GCH gene therapy (Nagatsu & Sawada, 2007). 
 
Based on research conducted by Shen et al in 2000, infusion of the three separate 
vectors AAV-TH, AAV-AADC, and AAV-GCH unilaterally in the striatum of 6-OHDA 
lesioned rats successfully demonstrated coexpression of TH, AADC, and GCH.  
 
 
Fig 8. Colocalization of TH, GCH, and AADC immunofluroesence staining in 
striatal tissue after AAV-TH, AAV-AADC, and AAV-GCH infusion. (A) TH 
staining using Rhodamine depicted in red. (B)AADC staining using FITC seen in 
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green. (C) Overlap of images A and B displaying colocalization of TH and GCH 
expression. (D) TH staining using Rhodamine depicted in red. (E) GCH staining 
using FITC seen in green, (F) Overlap of images D and E showing colocalization 
of TH and GCH proteins (Shen et al., 2000). 
 
The rats transduced with these three vectors were clinically evaluated by 
assessing the level of improvement in rotational behavior, in which the rats injected with 
AAV-TH, AAV-AADC, and AAV-GCH exhibited the greatest decrease in rotational rate 
compared to rats treated with only AAV-TH and AAV-AADC and the control group of 
AAV-LacZ. Further analysis through high performance liquid chromatography (HPLC) 
displayed the striatal BH4 and DA levels of the AAV-TH/AAV-AADC/AAV-GCH 
transduced rats were substantially higher in comparison to both the AAV-TH/AAV-
AADC group as well as the AAV-LacZ control (Shen et al., 2000). Shen et al were 
therefore able to support their claim that increasing levels of the three enzymes TH, 
AADC, and GCH leads to increased DA production in the PD rat model.  
 
Later studies reinforcing AADC-TH-GCH gene therapy as a promising method 
for improving the extreme motor impairment associated with PD utilized the lentiviral 
vector system modeled after the equine infectious anemia virus (EIAV) in which all three 
target genes are encoded from one transcriptional unit rather than three separate vectors 
(Azzouz et al, 2002). Through the work of Azzouz et al, in vitro rat striatal neurons 
transduced with the EIAV tricistronic vector displayed joint expression of AADC, TH, 
and GCH in striatal medium spiny neurons (MSN) by means of immunocytochemistry. 
Antibody staining against the tag epitopes HA-AADC, C-myc-TH, and Flag-CH1 
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detecting AADC, TH, and GCH protein expression respectively demonstrated 
colocalization in the transfected striatal MSN tagged with GAD. Furthermore, the 6-
OHDA lesioned rats infused with the three gene vector were clinically evaluated for 
motor improvement through the apomorphine induced rotational test in which a decrease 
in contralateral rotation was observed in the three gene transfected group as compared to 
the controls. This improvement in rotational behavior was also sustained throughout the 
testing period of 4 to 10 weeks after vector injection (Azzouz et al, 2002). 
 
The tricistronic lentiviral vector strategy for administering AADC-TH-GCH gene 
therapy advanced to phase 1/2 clinical trials in 2008 under the drug name ProSavin 
funded by Oxford BioMedica. The study was conducted as an open-label trial at two 
separate sites in which 15 PD patients meeting the specific inclusion criteria received 
bilateral ProSavin injections into the putamen (Palfi et al., 2014). Participants were 
subdivided into three treatment groups based on the dose of ProSavin resulting in a low 
dose group (dose level 1), mid dose group (dose level 2), and a high dose group (dose 
level 3). Researchers observed a total of 54 adverse events related to the administration of 
ProSavin within the first 12 months after putaminal injections, however these experiences 
of heightened dyskinesias and on-off phenomena were corrected by decreasing patient L-
DOPA dosage (Palfi et al., 2014). The trial also assessed UPDRS Part III scores during 
which in the OFF state, each patient presented a lower score at both 6 months and 12 
months post ProSavin treatment with no meaningful difference of scores between the 
three dose levels. In contrast, the UPDRS Part III ratings in the ON state failed to display 
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any significant improvement throughout the 12 month follow up period. UPDRS scores 
reported at 24 months, 36 months, and 48 months after receiving ProSavin treatment did 
not reflect further therapeutic improvement and increased in ratings which is most likely 
attributable to the advancement of PD. 
 
Table 2. Patient UPDRS scores. The total UPDRS scores for each individual patient in 
ON and OFF states reported throughout the four year observation period following 
ProSavin treatment (Palfi et al., 2014). 
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GAD Gene Therapy 
Delivery of the gene encoding for GAD, the key enzyme responsible for 
producing GABA, has potential to be an effective therapeutic approach for reducing the 
impact of the loss of dopaminergic neurons in PD. As nigrostriatal neurodegeneration 
progresses, the circuity of the basal ganglia is altered in such a way that the glutamatergic 
neurons of the STN are disinhibited, leading to increased excitatory signaling to the GPi 
and SNpr (Emborg et al., 2007). This overstimulation of the STN results in the observed 
motor symptoms of tremor, bradykinesia, and rigidity associated with PD. Through the 
application of GAD gene therapy, the hyperactive STN is restored to its normal 
functioning state by increasing the release of the inhibitory neurotransmitter GABA.  
 
Research examining the effectiveness of GAD gene therapy in relieving the 
symptoms of PD began through the administration of  rAAV vectors containing the GAD 
isoforms GAD65 and GAD67 in STN neurons of 6-OHDA lesioned rats (Luo et al., 
2002). GABA and glutamate levels in each of the five treatment groups (GAD65, 
GAD67, GFP, saline, and unlesioned control) were analyzed through microdialysis in the 
SNpr after applying electrical stimulation at the STN. Based on the collected data, the 
control group, 6-OHDA lesioned rats treated with GFP and those treated with saline 
presented no significant change in GABA or glutamate levels following electrode 
stimulation of the STN. The GAD65 treated group exhibited a significant increase in 
GABA levels after STN stimulation, and while the GAD67 treated rats responded to the 
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stimulation with a slight increase in GABA release, its levels were not comparable to the 
major increase observed in the GAD65 treatment group (Luo et al., 2002).  
 
 
Fig 9. Microdialysis analysis of GABA and glutamate levels in SNpr following 
electrical probe stimulation of STN. (A-E) The horizontal line noted represents the 5 
min period of electrical stimulation. GABA and glutamate concentrations collected from 
(A) unlesioned control rats and PD rat models treated with (B) saline (C) GFP (D) 
GAD65 and (E) GAD67. (F) Change in GABA concentration throughout the 60 min 
period in which each bar represents 15 min. GAD65 PD rats demonstrate increased 
GABA levels after STN stimulation (G) presents the change in glutamate concentration 
over the 60 min period with no significant change between the 5 treatment groups (Luo et 
al., 2002). 
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These findings are consistent in that STN stimulation of the control group 
(unlesioned rats) demonstrated an excitatory response in 74% of SNpr neurons. Both 
groups of the PD model rats treated with GFP and saline displayed a stronger excitatory 
response in 83% of SNpr neurons as expected due to the overactive and disinhibited STN 
associated with PD. Furthermore, the decrease in excitatory response to 17% and notable 
increase in inhibitory response to 78% of SNpr neurons in the GAD65 treated group 
indicates the successful expression of GAD in the STN and corresponding release of 
GABA inhibiting the overexcited SNr (Luo et al., 2002). 
 
Additional studies concentrating on the tolerability and therapeutic effect of GAD 
gene therapy include the work performed by Emborg et al on MPTP treated monkeys 
receiving unilateral infusions of either AAV-GAD or AAV-GFP in the STN. Through 
utilizing CRS, researchers assessed animal motor behavior of each group and found the 
animals transduced with GAD presented a steady decrease in CRS scores until eventually 
plateauing, whereas the control group infused with GFP showed an initial decrease in 
CRS scores which ultimately increased (Emborg et al., 2007). In addition, analysis of the 
GAD and GFP treated STN by means of fluorodeoxyglucose (FDG) PET imaging 
revealed a rise in glucose metabolism of the motor cortex in the AAV-GAD treated 
group, which researchers associate with successful GABA synthesis resulting in 
increased communication between the thalamus and motor cortex (Emborg et al., 2007). 
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Due to the promising results of GAD gene therapy seen in PD animal studies, 
AAV-GAD research progressed to phase I clinical trials under the guidance of Kaplitt et 
al. The open label study evaluated PD patients after STN injections of low dose, medium 
dose, or high dose AAV-GAD through measuring UPDRS scores in the ON and OFF 
states as well as recording activities of daily living (ADL) scores. UPDRS scores 
illustrated significant improvement among 10 of the 12 patients in both the ON and OFF 
states through the observation of lower scores corresponding to decreased episodes of 
motor fluctuation and dyskinesia. The Evaluation of UPDRS scores based on body side 
also indicated ameliorated brain function in that the UPDRS ratings of the body side 
contralateral to the AAV-GAD vector infusion displayed improvement relative to its 
pretreatment ratings. In contrast, the reported ADL scores failed to demonstrate 
significant improvement, however a trend towards improvement was detected in OFF 
state data. Researchers also noted that the patient daily dose of antiparkinsonian 
medication remained constant throughout the trial (Kaplitt et al., 2007). 
 
The more recent phase II clinical trial study conducted by Niethammer et al 
demonstrated the delivery of AAV-GAD into the STN of PD patient elicits a therapeutic 
response which is not observed in participating PD patients undergoing the sham surgery 
of injecting a vehicle control. Based on metabolic network analysis, PD patients 
administered AAV2-GAD in the STN illustrated a distinct treatment-related metabolic 
circuit which researchers refer to as the GAD related pattern (GADRP). Unlike the 
specific metabolic network attributed to PD known as the PD-related covariance pattern 
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(PDRP), GADRP bypasses the striatal and thalamic regions to form polysynaptic 
pathways directly increasing the connectivity of the STN to the premotor and motor 
cortex (Niethammer et al., 2018). The development of GADRP was also seen to directly 
correlate to the improvement of UPDRS scores in AAV2-GAD treated PD patients. 
Participants of the sham surgery group exhibited a polysynaptic pathway differing from 
PDRP as well called the sham-surgery related pattern (SSRP) resulting from the placebo 
effect, however, this pathway did not generate proportional clinical improvement seen 
through measured UPDRS scores (Niethammer et al., 2018). 
 
GDNF Gene Therapy 
Glial cell line derived neurotrophic factor (GDNF) is a prominent growth factor 
with neuroprotective abilities to prevent the degeneration of dopaminergic neurons (Gill 
et al., 2003). As PD pathology progresses, dopaminergic neurons of the nigrostriatal 
pathway continue to deteriorate and contribute to the decline in motor function 
experienced clinically by PD patients. Through GDNF gene therapy, the susceptible DA 
neurons are protected from neurotoxic exposures that lead to further neurodegeneration 
and consequently the worsening of PD symptoms (Gill et al., 2003). 
 
GDNF was originally introduced as a potential therapy option for PD through the 
work of Lin, Doherty, Lile, Bektesh, & Collins in which dissociated cultures of midbrain 
neurons from embryonic rats treated with recombinant human GDNF (hGDNF) 
demonstrated an increased survival of dopaminergic neurons. Researchers measured the 
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levels of dopamine uptake and TH expression in cultures treated with hGDNF as well as 
the untreated control and found the total cell count of midbrain neurons decreased by 
roughly 70% in the control group, while the hGDNF exposed culture experienced an 
overall neuronal degeneration of 70% but with a significantly greater portion of 
dopaminergic neurons remaining among the midbrain neurons (Lin et al., 1993).  Lin et al 
also noted an increase in DA uptake for the hGDNF treated cell culture as compared to 
the control group in addition to prominent morphological differences observed in the 
dopaminergic neurons such as larger cell bodies and increased differentiation within the 
hGDNF culture. 
 
The implementation of rAAV vectors as the delivery method for GDNF gene 
therapy was seen through the work of Eslamboli et al investigating the efficacy of rAAV-
GDNF treatment in 6-OHDA lesioned monkeys. The study consisted of two treatment 
groups in which one received unilateral injections of rAAV-GDNF in the substantia nigra 
and striatum referred to as the GDNF-L group, while the other was not injected with a 
viral vector and served as the control group termed CON-L. Each of the two groups 
underwent unilateral 6-OHDA lesions in the nigrostriatal bundle 4 weeks later allowing 
researchers to assess the regeneration of DA neurons through the quantification of DA 
cells in the SN (Eslamboli et al., 2003). The GDNF-L group displayed 40% of lesioned 
DA neurons remaining in the SN. In contrast, the CON-L group presented only 21% of 
the total lesioned DA neurons remaining, indicating that the GDNF-L group experienced 
protection of dopaminergic neurons through GDNF expression (Eslamboli et al., 2003). 
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Fig 10. Separate quantifications for TH-immunoreactive (TH-IR) and VMAT-
immunoreactive (VMAT-IR) cells in the SNpc. Cell counts of the lesioned and 
unlesioned SNpc were recorded for control CON-L and rAAV-GDNF treated GDNF-L 
group. The relative protection of cells was assessed by comparing the ratios of lesioned 
cells to unlesioned cells for each treatment group. Both TH-IR and VMAT-IR cells 
comparison of CON-L and GDNF-L ratios were statistically significant (p<0.05) 
(Eslamboli et al., 2003). 
 
TH immunohistochemistry was also utilized to illustrate the neuroprotection of 
DA neurons in the SN of the GDNF-L group, further supporting the efficacy of rAAV-
GDNF treatment.  
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Fig 11. TH immunochemistry of lesioned and unlesioned SN of CON-L and GDNF-
L treated monkeys. The top panel corresponds to CON-L treatment in which (A) is the 
intact tissue and (B) is the lesioned tissue. The bottom panel represents GDNF-L 
treatment in which (C) is the intact neural tissue and (D) is the lesioned tissue. 
Comparison of staining in (D) and (B) indicates the GDNF-L treated group preserved the 
TH-IR cells (Eslamboli et al., 2003). 
 
The first GDNF clinical trial conducted in 2003 under the guidance of Nutt et al 
assessed the neuroprotective effects of GDNF in patients suffering from advanced PD 
symptoms through intracerebroventricular (ICV) administration of recombinant human 
methionyl GDNF (r-methHuGDNF). This double-blind randomized study involved 50 
participants who received monthly ICV injections of either r-methHuGDNF at various 
different doses or placebo over an 8 month period and evaluated Parkinson symptoms by 
measuring total UPDRS and motor UPDRS scores for both the ON and OFF states, while 
GDNF safety and tolerability was assessed by observing subject vital signs. Through the 
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analysis of total and motor UPDRS scores recorded throughout the study, the GDNF 
treated group displayed no significant improvement in UPDRS ratings for the ON and 
OFF states compared to the placebo group. In addition, researchers detected no 
substantial difference in UPDRS score improvement for subjects of the GDNF group 
treated with higher doses of r-methHuGDNF (Nutt et al., 2003). Subject vital signs 
remained consistent in all categories except body weight in which participants of the 
GDNF treated group experienced weight loss equivalent to 5% or more of the subject’s 
body weight. Researchers also noted unfavorable episodes of nausea and vomiting in 
subjects following r-methHuGDNF injections at any dose (Nutt et al., 2003). 
 
After the unsuccessful outcome of Nutt et al’s phase I trial, researchers sought a 
different approach for delivering GDNF in the lesioned nigrostriatal pathway in an effort 
to enhance the restoration of degenerating dopaminergic neurons by means of directly 
targeting the putamen. In the phase I open label trial conducted by Gill et al, patients with 
severe idiopathic parkinsonism received bilateral catheter and pump implants at the level 
of the dorsal putamen for delivering GDNF. Evaluation of total UPDRS scores in the off 
state 12 months after receiving the GDNF treatment resulted in 48% decrease, and a 
similar improvement in total UPDRS scores in the on state was observed through a 45% 
decrease in ratings at the same time point following GDNF injections. Furthermore, the 
adverse effects of nausea, vomiting, and weight loss clinically demonstrated in the 
previous phase I trial of Nutt et al were not experienced by patients after receiving GDNF 
treatment. Additional analysis through [18F] DOPA PET images illustrated a 24.5% 
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increase of DA detected in the posterior putamen compared to its baseline DA levels 
prior to receiving GDNF (Gill et al., 2003). 
 
In a subsequent open label phase I trial led by Lang et al in 2006, the optimized 
GDNF delivery method of directly targeting the putamen did not present the same 
promising results as seen in the work of Nutt et al. The patients received bilateral 
intraputaminal injections of either human recombinant GDNF referred to as liatermin or a 
placebo control through intraparenchymal catheters and were assessed based on 
improvement of UPDRS scores following GDNF treatment. After 6 months of treatment, 
researchers reported no significant difference in UPDRS scores from the baseline values 
in each group as well as no substantial difference in UPDRS scores between the two 
treatment groups (Lang et al., 2006). Furthermore, participants experienced several 
adverse events as a result of the catheter implantation and presence of antiliatermin 
antibodies (Lang et al., 2006). 
 
NRTN Gene Therapy 
Structurally and functionally similar to GDNF, neurturin (NRTN) is an 
endogenous neurotrophic factor with the capability of preserving and enhancing the 
activity of dopaminergic neurons in the SN (Gasmi et al., 2007). Due to the progressive 
degeneration of DA neurons in the SN and subsequent loss of motor function occurring in 
PD patients, treatment through NRTN gene therapy protects the vulnerable DA neurons 
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from degrading and depleting the already low levels of DA within the nigrostriatal 
pathway. 
 
The use of NRTN as a therapeutic approach to minimize the dopaminergic 
neurodegeneration and alleviate the exhausting motor symptoms of PD was investigated 
in MPTP lesioned monkey striata by Herzog et al. In this study NRTN was delivered 
bilaterally to PD model NHP striata by the adeno-associated viral vector (AAV2-NRTN) 
referred to as CERE-120 at several different dose ranges and compared to a control group 
infused with formulation buffer (FB) (Herzog et al., 2008). Through analysis by means of 
immunohistochemistry targeting TH, the CERE-120 treated striata displayed significantly 
greater TH staining than the control group and demonstrated increased TH intensity 
within the striatal regions exhibiting strong NRTN labeling. Furthermore, TH 
immunoreactivity was observed to be directly proportional to the dose of CERE-120 
injected (Herzog et al., 2008). 
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Fig 12. TH-IR immunoreactivity staining of MPTP monkey striatal tissue. 
Striatal sections treated with (A)FB, (B) low dose CERE-120, (C) mid dose 
CERE-120, and (D) high dose CERE-120 were stained with TH-IR and measured 
for TH intensity (Herzog et al., 2008).  
 
In addition, the administration of CERE-120 failed to result in the unwanted 
effects of weight loss and decreased appetite as well as presented no alarming changes in 
neural tissues and peptides (Herzog et al., 2008). 
 
Due to the promising therapeutic benefits of CERE-120 demonstrated through 
animal studies, the approach of NRTN gene therapy by means of CERE-120 
intraputaminal infusions was able to progress towards an open label phase I clinical trial 
led by Marks et al. The study contained 12 PD patients which were equally divided into 
two treatment groups based on the vector dose of CERE-120 administered bilaterally 
through intraputaminal injections resulting in a low dose and high dose treatment group. 
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Improvement in behavioral function was assessed by motor UPDRS scores reported in 
the ON and OFF states in which the UPDRS rating in the OFF state exhibited a decrease 
of 36% one year after CERE-120 treatment. Researchers also noted a 25% mean increase 
in the time period between patient ON and OFF states (Marks et al., 2008), indicating that 
that patients were experiencing more time without motor fluctuations. Other aspects of 
the UPDRS patient scores however did not demonstrate significant improvement one 
year following CERE-120 injections such as hand dexterity and activities of daily living 
(Marks et al., 2008). In addition, analysis of the intraputaminal CERE-120 infusions by 
18F-DOPA PET imaging presented no visible change in L-DOPA uptake for both CERE-
120 vector dose groups compared to their respective pre-treatment L-DOPA metabolism 
(Marks et al., 2008). 
 
Further studies focused on enhancing AAV2-NRTN gene therapy were performed 
by Warren Olanow et al in which researchers examined the effect of AAV2-NRTN 
vector delivery by targeting both the SNpc and striatum rather than solely the putamen. 
Warren Olanow et al believed that directly treating the SNpc as well as the putamen with 
AAV2-NRTN would elicit a greater improvement in behavioral response within a shorter 
time period. In this randomized double blind phase I trial, 51 patients diagnosed with 
advanced PD were either administered bilateral injections of AAV2-NRTN at the SNpc 
and putamen or underwent sham surgery to serve as a control. Patients were evaluated by 
UPDRS part III scores in the off state over a 15 month period in which no significant 
difference in UPDRS scores was observed between the AAV2-NRTN treated group and 
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sham surgery group. Each treatment group however demonstrated a decrease in UPDRS 
motor scores relative to its respective baseline score throughout the course of the study 
(Warren Olanow et al., 2015). 
 
 
Fig 13. Long term analysis of the change in UPDRS scores. UPDRS motor 
scores in OFF state were recorded from pre-treatment baseline to 24 months after 
treatment in sham surgery group and AAV2-NRTN treated group. Both treatment 
groups presented a similar trend of improvement in UPDRS scores (p < 0.01) 
(Warren Olanow et al., 2015). 
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DISCUSSION 
 	 Although the concept of gene therapy as a therapeutic strategy for 
diminishing the symptoms of PD is quite novel, it has been suggested to be an effective 
addition to the current PD treatment regimen. With the concurrent decrease in L-DOPA 
therapeutic effect and destructive progression of PD pathology, patients suffering from 
advanced PD require a supplementary treatment approach to maintain motor function and 
regulate the heightened symptoms of PD. Gene therapy offers the potential to control DA 
production and dopaminergic neuron phenotype. Through the therapeutic benefits of 
correcting PD motor deficits and reducing the presence of L-DOPA induced dyskinesia, 
gene therapy could provide substantial therapeutic improvement for PD patients.  
The specific mechanisms underlying PD gene therapy treatment each involve the 
use of viral vector-mediated gene delivery. This approach is preferred by researchers 
because it allows specific targeting of the nigrostriatal pathway affected by PD 
pathophysiology without targeting additional unwanted brain areas. Viral vectors are also 
easily diffusible and therefore able to efficiently reach the striatum after a single 
injection. In addition, particular genes have been recognized as capable of restoring DA 
levels (AADC, AADC-TH-GCH, and GAD) as well as protecting against neural 
degeneration (GDNF and NRTN) (Feng & MAquire-Zeiss, 2010). 
 
Based on the collection of studies focusing on the efficacy of AADC gene 
therapy, intraputaminal delivery of AAV-hAADC in PD patients demonstrates a 
promising therapeutic method through the significant improvement of UPDRS scores in 
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the OFF state reported 6 months following treatment (Christine et al., 2009). This 
dramatic change in UPDRS scores however may be subject to the placebo effect due to 
the open label nature of the study. Further research with a control placebo group as well 
as more subjects would be beneficial in determining a more accurate effect of AAV-
hAADC injections on UPDRS scores. In addition, increasing the vector dose may result 
in an enhanced therapeutic effect.  
 
The gene therapy mechanism involving the three gene approach AADC-TH-GCH 
presents an advantage over the AADC therapy option in that patients may be able to stop 
oral L-DOPA treatment completely. The findings of the phase 1/2 clinical trial for 
ProSavin presented promising results in that each dose group of treated PD patients 
displayed improved OFF state UPDRS scores at 6 and 12 months after treatment, 
however the scores were not found to be dose dependent (Palfi et al., 2014). Future 
investigations with a control group to serve as a reference for improvement should be 
implemented for a better assessment of the therapeutic effect. In comparison to AADC 
gene therapy, the AADC-TH-GCH approach may be less effective in improving PD 
symptoms since current studies have found it to be dose independent, however further 
research assessing each treatment method in relation to a control group is necessary to 
observe the full therapeutic benefit.  
 
The administration of AAV-GAD is perhaps the most advanced method of gene 
therapy for improving the symptoms of PD as seen through the successful outcome of the 
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blind Phase II clinical trial conducted by Niethammer et al. The PD patients treated with 
AAV-GAD presented a distinct metabolic network between the STN and motor cortex 
termed GADRP that not only differed from the known PD metabolic pathway in the STN 
but also resulted in a corresponding improvement of motor UPDRS scores. The study 
also included a sham surgery group that despite exhibiting its own polysynaptic pathway 
different from both the GADRP and PDRP did not show clinical improvement in UPDRS 
scores (Niethammer et al., 2018). Researchers should consider incorporating more 
subjects into each treatment group to divert the strong placebo effect experienced by 
patients in the sham surgery group interfering with forming an impartial observation of 
the treatment response. A long term follow-up of the involved patients would also be 
beneficial in assessing GAD gene therapy effectiveness. In addition, GADRP can be 
utilized in future studies as a biomarker for positive AAV-GAD treatment responses and 
assist in distinguishing the patients experiencing a placebo effect from those undergoing a 
true therapeutic response. 
 
The recent efforts to promote GDNF gene therapy as a promising therapeutic 
strategy for PD have been somewhat unreliable due to the conflicting outcomes of phase I 
clinical trials. The open label study conducted by Gill et al in which GDNF was 
administered to the putamen via catheter pumps demonstrated notable improvement in 
motor response measured by UPDRS scores as well as fewer negative side effects of 
nausea, vomiting, and weight loss observed in previous studies. A later open label phase I 
study however did not produce the same encouraging results. Instead of delivering GDNF 
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through catheter implant pumps, the gene vector was directly injected into the putamen 
and displayed no clinical improvement based on UPDRS scores both compared to pre-
treatment baseline as well as the control group (Lang et al., 2006). This discrepancy in 
results provokes the need for additional studies to optimize the delivery method of GDNF 
into the putamen. Although a direct putaminal injection of GDNF is ideal, researchers 
must assess which delivery method provides the best vector distribution to the brain 
region of interest.  
 
NRTN gene therapy studies have also presented conflicting results in targeting the 
symptoms of PD in which the NRTN adeno-associated viral vector known as CERE-120 
has demonstrated success in animal models (Herzog et al., 2008), however failed to 
produce meaningful results in human studies. Phase I clinical trials with CERE-120 
delivery via intraputaminal infusions as well as CERE-120 delivery to both the SNpc and 
putamen displayed insignificant improvement of motor function compared to the control 
group (Gill et al., 2003; Warren Olanow et al., 2015). Possible factors contributing to the 
unsuccessful human trials include insufficient delivery of CERE-120 to fully saturate the 
target area and severe axonal dysfunction due to PD progression. Further research studies 
should address these issues by increasing the administered vector dose of CERE-120 to 
promote distribution and enroll patients at an earlier stage of PD to better assess the 
therapeutic effect of NRTN gene therapy. 
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CONCLUSION 
 	 The application of gene therapy in treating PD presents significant promise in 
addressing the challenges of managing the life impairing symptoms and inevitable 
disease progression. Several clinical trials have demonstrated positive results in 
alleviating the behavioral symptoms of PD, however further research focusing on 
treatment methods for preventing PD disease development as well as regaining normal 
physiology is needed. AADC gene therapy in addition to the three gene target approach 
of AADC-TH-GCH gene therapy have exhibited successful clinical trails thus far by 
proving to be effective in lowering the dose of L-DOPA needed to elicit a therapeutic 
response in patients with advanced PD. The administration of GAD gene therapy in PD 
patients has also presented clinical improvement of symptoms while maintaining 
treatment safety. With the promising direction of these gene therapies, additional clinical 
trials are required to confirm the therapeutic effectiveness and investigate their 
coadministration with other PD therapy options expanding beyond L-DOPA. 
 The delivery of neurotrophic factors GDNF and NRTN through gene therapy as a 
means of preserving the dopaminergic neurons of the SNpc remains a topic of active 
research due to the inconclusive evidence presented by preliminary clinical trials to date. 
Current concerns in growth factor gene therapy research include the use of patients with 
such an extensive PD disease progression that DA neurons are no longer present to 
experience the protective effects of GDNF and NRTN gene administration. Clinical 
investigations should therefore target patients with confirmed early stage PD to ensure 
that pathological neurodegeneration has not completely damaged the SNpc. The accuracy 
	45 
of PD animal models also poses an obstacle in conducting GDNF and NRTN gene 
therapy studies due to inconsistent pathophysiology between the PD induced animal 
models and PD patients. The PD animal models (6-OHDA treated mice and MPTP 
treated monkeys) display behavioral symptoms accurately matching those of PD patients, 
but do not exhibit a similar PD neuropathology. Through genetically engineering a PD 
animal model that fully portrays PD pathology, the GDNF and NRTN gene therapy 
strategies can be better evaluated as potential disease modifying therapies for PD.  
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